Ardelyx Inc (NASDAQ:ARDX) — Market Cap & Net Worth
Market Cap & Net Worth: Ardelyx Inc (ARDX)
Ardelyx Inc (NASDAQ:ARDX) has a market capitalization of $1.37 Billion ($1.37 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7780 globally and #2254 in its home market, demonstrating a 2.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ardelyx Inc's stock price $5.67 by its total outstanding shares 247029387 (247.03 Million). Review Ardelyx Inc (ARDX) financial obligations to assess the company's total debt and financial obligations.
Ardelyx Inc Market Cap History: 2015 to 2026
Ardelyx Inc's market capitalization history from 2015 to 2026. Data shows change from $4.48 Billion to $1.40 Billion (-10.84% CAGR).
Index Memberships
Ardelyx Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.06% | #216 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #834 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.08% | #133 of 263 |
Weight: Ardelyx Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ardelyx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ardelyx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.54x
Ardelyx Inc's market cap is 3.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.51 Billion | $24.03 Million | -$112.39 Million | 146.00x | N/A |
| 2017 | $1.63 Billion | $42.00 Million | -$64.34 Million | 38.82x | N/A |
| 2018 | $442.18 Million | $2.61 Million | -$91.30 Million | 169.61x | N/A |
| 2019 | $1.85 Billion | $5.28 Million | -$94.94 Million | 351.06x | N/A |
| 2020 | $1.60 Billion | $7.57 Million | -$94.31 Million | 211.11x | N/A |
| 2021 | $271.73 Million | $10.10 Million | -$158.16 Million | 26.91x | N/A |
| 2022 | $704.03 Million | $52.16 Million | -$67.21 Million | 13.50x | N/A |
| 2023 | $1.53 Billion | $124.46 Million | -$66.07 Million | 12.31x | N/A |
| 2024 | $1.25 Billion | $333.62 Million | -$39.14 Million | 3.75x | N/A |
| 2025 | $1.44 Billion | $407.32 Million | -$61.60 Million | 3.54x | N/A |
Competitor Companies of ARDX by Market Capitalization
Companies near Ardelyx Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Ardelyx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Ardelyx Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Ardelyx Inc's market cap moved from $4.48 Billion to $ 1.40 Billion, with a yearly change of -10.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.40 Billion | -2.74% |
| 2025 | $1.44 Billion | +14.99% |
| 2024 | $1.25 Billion | -18.23% |
| 2023 | $1.53 Billion | +117.54% |
| 2022 | $704.03 Million | +159.09% |
| 2021 | $271.73 Million | -83.00% |
| 2020 | $1.60 Billion | -13.79% |
| 2019 | $1.85 Billion | +319.27% |
| 2018 | $442.18 Million | -72.88% |
| 2017 | $1.63 Billion | -53.52% |
| 2016 | $3.51 Billion | -21.63% |
| 2015 | $4.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Ardelyx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.37 Billion USD |
| MoneyControl | $1.37 Billion USD |
| MarketWatch | $1.37 Billion USD |
| marketcap.company | $1.37 Billion USD |
| Reuters | $1.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more